Treatment of HER2-positive breast cancer.
Treatment of HER2-positive breast cancer.
复制标题
DOI：
10.1016/j.breast.2013.11.011
复制
发表时间：
2014-04
期刊：
影响因子：
3.9
通讯作者：
Wolff, Antonio C.
中科院分区：
文献类型：
--
作者：
Figueroa-Magalhaes, Maria Cristina;Jelovac, Danijela;Connolly, Roisin M.;Wolff, Antonio C.
人表皮生长因子受体2基因（HER 2）在约15%的乳腺癌患者中过表达和/或扩增，并在四分之一世纪前被确定为预后不良的标志物。到1998年，靶向HER 2途径的抗体治疗显示出明显改善转移性疾病的无进展生存期和总生存期，2005年，第一代曲妥珠单抗辅助试验的无疾病生存期和总生存期改善的证据变得可用。然而，并非所有HER 2过表达的患者都能从曲妥珠单抗中获益。转移性疾病的第二代研究导致几种新的HER 2靶向疗法获得批准，这些疗法使用小分子酪氨酸激酶抑制剂如拉帕替尼、新的HER 2/HER 3抗体如帕妥珠单抗和新的抗体化疗偶联物ado-曲妥珠单抗emtansine。这些成功支持了第二代辅助试验的启动，这些试验测试了单一和双重HER 2靶向药物，与化疗同时或顺序给药，很快将完成招募。HER 2靶向治疗背景下的HER 2阳性乳腺癌不再与预后不良相关，美国食品和药物管理局最近的指导表明，术前给予的HER 2靶向治疗的病理学反应可能允许在辅助治疗背景下对其临床获益进行早期评估。在肿瘤表达正常水平HER 2的患者中进行的曲妥珠单抗辅助试验和无化疗的单/双重HER 2靶向试验也正在进行中。在这篇文章中，我们回顾了目前的数据对HER 2阳性乳腺癌的治疗管理。
The human epidermal growth factor receptor 2 gene (HER2) is overexpressed and/or amplified in ~ 15% of breast cancer patients and was identified a quarter century ago as a marker of poor prognosis. By 1998, antibody therapy targeting the HER2 pathway was shown to demonstrably improve progression-free and overall survival in metastatic disease, and in 2005 evidence of improvement in disease-free and overall survival from the first generation of trastuzumab adjuvant trials became available. However, not all patients with HER2 overexpression benefit from trastuzumab. Second-generation studies in metastatic disease led to the approval of several new HER2-targeted therapies using small molecule tyrosine kinase inhibitors such as lapatinib, new HER2/HER3 antibodies such as pertuzumab, and the new antibody chemotherapy conjugate ado-trastuzumab emtansine. These successes supported the launch of second-generation adjuvant trials testing single and dual HER2-targeted agents, administered concomitantly or sequentially with chemotherapy that will soon complete accrual. HER2-positive breast cancer in the setting of HER2-targeted therapy is no longer associated with poor prognosis, and recent guidance by the US Food and Drug Administration suggests that pathologic response to HER2-targeted therapy given preoperatively may allow an earlier assessment of their clinical benefit in the adjuvant setting. An adjuvant trial of trastuzumab in patient whose tumors express normal levels of HER2 and trials of single/dual HER2-targeting without chemotherapy are also ongoing. In this article, we review the current data on the therapeutic management of HER2-positive breast cancer.
登录
查看更多内容
影响因子：
3.8
作者：
Cameron, David;Casey, Michelle;Geyer, Charles E.
通讯作者：
Geyer, Charles E.
影响因子：
51.1
作者：
Bachelot, Thomas;Romieu, Gilles;Labbe-Devilliers, Catherine
通讯作者：
Labbe-Devilliers, Catherine
影响因子：
45.3
作者：
Burstein, Harold J.;Sun, Yan;Badwe, Rajendra
通讯作者：
Badwe, Rajendra
影响因子：
45.3
作者：
Burris, Howard A., III;Rugo, Hope S.;O'Shaughnessy, Joyce A.
通讯作者：
O'Shaughnessy, Joyce A.
影响因子：
45.3
作者：
Di Leo, Angelo;Gomez, Henry L.;Press, Michael F.
通讯作者：
Press, Michael F.